Eli Lilly's Investigational Drug Shows Potential in Diabetes Management
Eli Lilly's investigational drug, known as 'triple-G', has demonstrated significant effects on blood sugar and weight in a late-stage diabetes trial.
In a recent late-stage trial, Eli Lilly's investigational drug, 'triple-G', has shown promise for diabetes patients, leading to notable reductions in blood sugar levels.
Participants in the study also experienced significant weight loss, suggesting the drug may have dual benefits for those managing diabetes.
While the results are encouraging, further research will be necessary to fully understand the long-term effects and potential side effects associated with the drug.
Updates
Update at 10:45 UTC on 2026-05-21
STAT reported A next-gen Eli Lilly obesity drug led to bariatric-surgery levels of weight loss in a study, but also saw patients dropping out because of side effects.
Sources: STAT